secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-06-08T20:19:40+00:00
Accession:  0001534120-26-000036
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics shareholders approve Second Amended ESPP at 2026 annual meeting
--------------------------------------------------------------------------------

- ESPP share reserve set at 961,608 shares; annual evergreen of lesser of 4M shares or 1% of outstanding common stock through 2036.
- Purchase price at 85% of FMV on either offering date or purchase date, whichever is lower; payroll deductions up to 15% of earnings.
- All seven director nominees elected with >99% of votes cast in favor (e.g., Michael Heffernan: 21,101,978 for, 624 withheld).
- Ratification of Ernst & Young as independent auditor approved with 22,513,332 for vs 153,320 against and 5,632 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000036/0001534120-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000036/avtx-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer